Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737167 | 0.76 | MAPT (0.42) | HDAC3HDAC1HDAC2NCOR2ELANE | |
| SCHEMBL4514786 | 0.74 | ALDH1A1 (0.43) | HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6529111 | 0.72 | GPR119 (0.46) | GPR119HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL29067296 | 0.71 | GPR119 (0.45) | GPR119 | |
| SCHEMBL25436784 | 0.66 | AAK1 (0.32) | — | |
| SCHEMBL6650117 | 0.65 | MPO (0.48) | — | |
| SCHEMBL1179129 | 0.65 | ACACB (0.32) | GPR119 | |
| SCHEMBL29277587 | 0.65 | ALDH1A1 (0.46) | HDAC1 | |
| SCHEMBL1401073 | 0.65 | PARP1 (0.46) | — | |
| SCHEMBL1706932 | 0.64 | HDAC6 (0.38) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6709679-B2 | CONSISTING OF NATIVE OR THIOLATED TRANSFERRIN OR ALBUMIN OR OF POLYETHYLENE GLYCOL WITH ATLEAST ONE MERCAPTAN, HYDROXY OR AMINE GROUP AND CYTOSTATIC COMPOUNDS DERIVED THROUGH MALEINIMIDE OR HYDROXYSUCCINIMIDE ESTER COMPOUNDS | KRATZ FELIX (DE) | 2004-03-23 | — | — | US | disclosed |
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | KRATZ FELIX (DE) | 2002-02-14 | — | — | US | disclosed |
| US-6310039-B1 | TUMOR-INHIBITING CONJUGATES OF PROTEINS AND POLYMERS CONSISTING OF A SUITABLE CARRIER SYSTEM AND CYTOSTATIC COMPOUNDS | KRATZ FELIX (DE) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019343-A1 | Antineoplastic conjugates of transferrin, albumin and polyethylene glycol | TFRC, ALB, FOLR1 | GPR119 3065/4885HDAC3 2145/4885HDAC1 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.